Firstmed Blog

There’s been a lot in the press over the last couple of days about the dangers of online pharmacies. I will be writing a more in-depth article but in the mean time I would just like to comment briefly on the issue.

The wave of recent press on the subject is as a result of a report released by an online brand management company, Mark Monitor’s, whose research found that the majority of online drug retail websites operate without proper credentials and lack e-commerce security features.

Most importantly, on an ethical level, dubious online pharmacies are putting the health and wealth of customers at risk by operating without proper credentials and lacking even the most basic e-commerce security features. On a business level, illegal operators are jeopardizing the future of online business and denying consumers a more convenient and private way to shop.

Here at Firstmed we are constantly reaffirming the things to look out for when shopping online. Patients considering purchasing medicines via the internet should be encouraged to verify the website is operated from a registered retail pharmacy within the UK. This is to ensure their medicines are obtained from a reputable source and accurate and appropriate advice in relation to their medicines is received.

200 years ago Parkinson’s disease was first discovered, but little progress has been made since then about the cause. Now, in the largest study of its kind, researchers from the Mayo Clinic have discovered that genetics may play a small but significant role in determining one’s risk for the disease.

The study found that genes play as much as a 3 percent role in one’s overall risk for developing Parkinson’s disease. With this new information, further research on the role of these genes may lead to better treatments or even a cure.

This is an important step forward, said a lead study investigator, because the contribution of common genetic risk factors to the development of Parkinson’s has long been suspected.
The researchers collected genetic information from almost 2,700 patients with Parkinson’s disease and compared it with that of healthy men and women of the same age. They found that in many of the Parkinson’s patients, there was one segment of DNA that was a bit longer than in the healthy patients. This section of DNA supports the expression of another gene, alpha-synuclein. So, in Parkinson’s patients this gene is over expressed, or turned on more than in a person without Parkinson’s disease.

While it is not yet known how this genetic defect leads to Parkinson’s, the researchers were able to determine that people with the extra-long DNA segment have a 1.5 greater risk for Parkinson’s disease than someone who doesn’t.

Parkinson’s disease affects around 1 million people in the United States and causes the decay of brain cells. This can cause symptoms of uncontrollable shaking, stiffness, imbalance and uncoordinated movements. There are a few treatments to reduce these symptoms, but, in general, their impact is short-lived.

With this new information, however, researchers can turn their attention to the alpha-synuclein gene.

Findings support the development of therapies that reduce alpha-synuclein gene expression. Such therapies have the potential to prevent or delay the beginning of Parkinson’s disease or to stop or slow its progression.